--- title: "What's Going On With CNS Pharmaceuticals Stock On Wednesday?" type: "News" locale: "en" url: "https://longbridge.com/en/news/285391947.md" description: "CNS Pharmaceuticals Inc. (NASDAQ:CNSP) is shifting to an acquisition-led strategy, focusing on clinical-stage assets in neurology and oncology. The stock rose nearly 9% following the announcement of a capital raise, selling 650,000 shares at $2.30 each. Currently priced at $7.63, the stock shows bullish momentum but is considered overbought, with key resistance at $9.00 and support at $5.88. Despite the strategic pivot, the company's momentum score indicates underperformance compared to the broader market, suggesting caution for investors." datetime: "2026-05-06T13:51:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285391947.md) - [en](https://longbridge.com/en/news/285391947.md) - [zh-HK](https://longbridge.com/zh-HK/news/285391947.md) --- # What's Going On With CNS Pharmaceuticals Stock On Wednesday? **CNS Pharmaceuticals Inc.** (NASDAQ:CNSP) shares are up during Wednesday's premarket session. The company on Tuesday announced a strategic pivot to acquire clinical-stage assets with identifiable near-term value, sending shares higher and then closing around 9% on Tuesday. The move follows the recent news of a capital raise, where CNS Pharmaceuticals has entered into securities purchase agreements to sell 650,000 shares at a price of $2.30 each, along with pre-funded warrants for 9,143,479 shares at $2.299 per warrant, expected to close around May 5, 2026. The company aims to use these funds to support its new corporate strategy announced in March 2026. **Read Also: Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View** ## CNS Pharmaceuticals Pivot: Acquisition-Driven Neurology And Oncology Pipeline CNS Pharmaceuticals is pivoting from its previous focus on glioblastoma multiforme treatments to a new growth strategy centered on building a high-value pipeline in neurology and oncology. This shift includes actively discussing out-licensing its legacy glioblastoma programs, allowing the company to focus on acquiring differentiated assets with strong clinical and commercial potential. ## CNSP Technical Outlook: Bullish Momentum And Key Levels The stock's current price of $7.63 is significantly above its 20-day simple moving average (SMA) of $2.92, indicating strong bullish momentum. The relative strength index (RSI) currently sits at 81.59, suggesting that the stock is overbought, which may indicate a potential pullback in the near term. **Key Resistance**: $9.00 — a nearby level where rebounds can stall. **Key Support**: $5.88 — This level aligns with the 200-day SMA, providing a potential floor for the stock. ## How CNSP Ranks On Momentum Versus The Market Below is the Benzinga Edge scorecard for CNS Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market: - **Momentum**: Weak (Score: 25.37) — Stock is underperforming the broader market. **The Verdict:** CNS Pharmaceuticals' Benzinga Edge signal reveals a weak profile, indicating challenges in gaining traction within the market. The company's focus on a new strategic direction may provide future opportunities, but current momentum suggests caution for investors. **CNSP Price Action:** CNS Pharmaceuticals shares were up 4.90% at $7.50 at the time of publication on Wednesday, according to Benzinga Pro data. Photo: Gorodenkoff via Shutterstock **Read Also: Top 2 Tech Stocks That May Fall Off A Cliff This Month** ### Related Stocks - [CNSP.US](https://longbridge.com/en/quote/CNSP.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) ## Related News & Research - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [](https://longbridge.com/en/news/286787081.md) - [CNS Pharmaceuticals Announces Private Placement and Board Changes](https://longbridge.com/en/news/285064548.md)